Abstract
It was explored that CYP1 family of cytochromes P450 were over-expressed in several types of cancer. Our study aimed to characterize anti-proliferative activity and metabolism of the natural flavonoid diosmetin in the human hepatoma cell HepG2, expressing CYP1 family. Diosinduced cell apoptosis could be reversed due to p53 blockade and the cellular P53 and CYP1A1/CYP1A2 proteins levels were examined. P53 and CYP1A1/CYP1A2 proteins were upregulated by Dios; when PFT-α was added into cells, the P53 levels were down-regulated accompanied with up-regulated CYP1A1/CYP1A2. Meanwhile, when cells were co-treated with Dios and PFT-α, P53 was down-regulated and CYP1A1/CYP1A2 up-regulated controlled with that of Dios treated cells. The data reveal the new evidence that cytochrome P450 CYP1A regulation by P53 enzyme plays an important role in Diosmetin anti-cancer activity of HepG2 cells.
Keywords: Diosmetin, HepG2, CYP1A1/CYP1A2, PFT-α, Apoptosis, P53.
Graphical Abstract
Protein & Peptide Letters
Title:Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells
Volume: 24 Issue: 5
Author(s): Bin Liu, Kaiqiao Jia, Yu Yang, Siyuan Hao, Caijie Lu, Fengming Xu*, Dehui Feng*Runzhi Zhu*
Affiliation:
- Pediatrics, Affiliated Hospital of Guangdong, Medical University, Zhanjiang, 524001, Guangdong Province,China
- Elderly Medical Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524001, Guangdong Province,China
- Laboratory of Hepatobiliary Surgery, Guangdong Medical University, Zhanjiang Key Laboratory of Hepatobiliary Diseases, North 57th of Renmin Road, Zhanjiang, 524001, Guangdong,China
Keywords: Diosmetin, HepG2, CYP1A1/CYP1A2, PFT-α, Apoptosis, P53.
Abstract: It was explored that CYP1 family of cytochromes P450 were over-expressed in several types of cancer. Our study aimed to characterize anti-proliferative activity and metabolism of the natural flavonoid diosmetin in the human hepatoma cell HepG2, expressing CYP1 family. Diosinduced cell apoptosis could be reversed due to p53 blockade and the cellular P53 and CYP1A1/CYP1A2 proteins levels were examined. P53 and CYP1A1/CYP1A2 proteins were upregulated by Dios; when PFT-α was added into cells, the P53 levels were down-regulated accompanied with up-regulated CYP1A1/CYP1A2. Meanwhile, when cells were co-treated with Dios and PFT-α, P53 was down-regulated and CYP1A1/CYP1A2 up-regulated controlled with that of Dios treated cells. The data reveal the new evidence that cytochrome P450 CYP1A regulation by P53 enzyme plays an important role in Diosmetin anti-cancer activity of HepG2 cells.
Export Options
About this article
Cite this article as:
Liu Bin, Jia Kaiqiao, Yang Yu, Hao Siyuan, Lu Caijie, Xu Fengming*, Feng Dehui*, Zhu Runzhi*, Diosmetin Induces Cell Apoptosis by Regulating CYP1A1/CYP1A2 Due to p53 Activation in HepG2 Cells, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170227123557
DOI https://dx.doi.org/10.2174/0929866524666170227123557 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry Genetic Dissection of Complex Traits In Silico: Approaches, Problems and Solutions
Current Bioinformatics Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Scalarane Sesterterpenoids
Current Bioactive Compounds Prometheus: The Supreme Court Redefines the Patentability of Diagnostic Inventions
Recent Patents on DNA & Gene Sequences Selection of Reprogramming Factors of Induced Pluripotent Stem Cells Based on the Protein Interaction Network and Functional Profiles
Protein & Peptide Letters Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Anticancer Effects of Garlic and Garlic-derived Compounds for Breast Cancer Control
Anti-Cancer Agents in Medicinal Chemistry Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force
Current Nanomedicine Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Formulation, Characterization and In vitro Cytotoxicity of 5-Fluorouracil Loaded Polymeric Electrospun Nanofibers for the Treatment of Skin Cancer
Recent Patents on Nanotechnology Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Baicalein - An Intriguing Therapeutic Phytochemical in Pancreatic Cancer
Current Drug Targets